Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.58), $0.10 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $12.55 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Iridium launches hybrid IoT module combining satellite and cellular
• H.C. Wainwright Reiterates Buy Rating on Tscan Therapeutics Inc (TCRX)